 |
|
The Adverse Events of Chemotherapy for RetinoblastomaWhat Are They? Do We Know?
Allison E. Rizzuti, BA;
Ira J. Dunkel, MD;
David H. Abramson, MD
Arch Ophthalmol. 2008;126(6):862-865.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
External beam radiation (EBR) is an effective treatment for intraocular retinoblastoma, as it has been shown to save children's vision as well as their lives. While once standard therapy, and despite its success, EBR has largely been abandoned, owing to the concern of secondary malignancies,1 and has been replaced with systemic multiagent chemotherapy. It is unusual in cancer treatment that the decision for successful treatment be based not on the immediate result (eliminating the cancer), but rather on complications that may develop many (> 30) years later. Nonetheless, in the last 10 years there has been a shift in treatment preference, and numerous authors have reported favorable outcomes using various drug regimens.2-13 It has been demonstrated that Reese-Ellsworth groups I-V can be successfully treated with either EBR or multiagent systemic chemotherapy followed by focal treatments. Patient and ocular survival . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Molecular Sequelae of Histone Deacetylase Inhibition in Human Retinoblastoma Cell Lines: Clinical Implications
Poulaki et al.
IOVS 2009;50:4072-4079.
ABSTRACT
| FULL TEXT
Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides
Antczak et al.
IOVS 2009;50:3065-3073.
ABSTRACT
| FULL TEXT
|
